Experimental anti-malarial drug shows promise in first clinical trial
Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
SJ733 is one of the first in a new class of anti-malarial compounds to reach clinical trials. It works by disrupting the malaria parasite's ability to remove excess sodium from red blood cells. As sodium builds up, infected cells become less flexible. The cells are removed by the immune system or get caught in small blood vessels.A total of 38 healthy volunteers were recruited as part of the Phase 1a study in Memphis and Phase 1b study in Brisbane, Australia. The 23 healthy volunteers in Memphis received increasing doses of SJ733 as part of the first-in-human study to understand SJ733 dosing, safety profile and metabolism, including absorption.
Based on those results the 15 Australian volunteers received SJ733 after being infected with malaria to understand the anti-malarial effectiveness of this new drug. The participants later received a curative dose of conventional anti-malarial combination therapy.No significant SJ733 treatment-related side-effects were identified in any of the volunteers.
For more details: https://pharmacology.healthconferences.org/
Contact: pharmafroum@theexpertsmeet.com
Whats app: +44 7426056247
No comments:
Post a Comment